Oxford BioMedica Says Sanofi to Terminate Collaboration, License Agreement
March 19 2021 - 4:23AM
Dow Jones News
By Matteo Castia
Oxford BioMedica PLC said Friday that French pharma group Sanofi
SA intends to terminate its collaboration and license agreement
with Oxford BioMedica in the field of hemophilia gene therapy.
The gene and cell-therapy group said it expects a negligible
impact on revenue in the next 24 months due to the termination.
Write to Matteo Castia at matteo.castia@dowjones.com
(END) Dow Jones Newswires
March 19, 2021 04:08 ET (08:08 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024